THERAPY DOSSIER · th-6c937cea2a59

Wild type CD11b+ monocytes (adoptive transfusion), unstimulated or stimulated with interferon-gamma or interleukin-4

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24602320 ↗2014Mixed findings

Distinct CD11b+-monocyte subsets accelerate endothelial cell recovery after acute and chronic endothelial cell damage.

MouseOtherCD11b-diphtheria toxin receptor mice and ApoE-/- CD11b-DTR mice; wild type donor cellsTransfusionAfter endothelial injury, with assessment at 7 days

Model: Acute carotid endothelial injury in monocyte-depleted CD11b-DTR mice and chronic hypercholesterolaemia-induced endothelial injury in ApoE-/- CD11b-DTR mice

CD11b+ monocytes improved endothelium-dependent vasoreactivity 7 days after acute injury and homed to the injury site, whereas CD11b-negative cells had no effect. In chronic hypercholesterolaemic injury, interferon-gamma stimulated monocytes decreased endothelial function while interleukin-4 stimul…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…